Why AbCellera Biologics Inc.’s (ABCL) Stock Is Down 7.81%
As of Monday, July 20, AbCellera Biologics Inc.’s ABCL share price has dipped by 7.81%, which has investors questioning if this is right time to buy.Jenna Brashear
Stock Evaluator: AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. ABCL
$5.71
0.02
0.35%
July 31, 2026 4:00:00 PM
EST
Volume: 4,953,705
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Commentary & Analysis
Why AbCellera Biologics Inc.’s (ABCL) Stock Is Down 5.93%
As of Thursday, July 16, AbCellera Biologics Inc.’s ABCL share price has dipped by 5.93%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why AbCellera Biologics Inc.’s (ABCL) Stock Is Down 5.69%
As of Friday, July 10, AbCellera Biologics Inc.’s ABCL share price has dipped by 5.69%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why AbCellera Biologics Inc.’s (ABCL) Stock Is Up 5.21%
As of Thursday, July 09, AbCellera Biologics Inc.’s ABCL share price has surged by 5.21%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why AbCellera Biologics Inc.’s (ABCL) Stock Is Down 8.19%
As of Wednesday, July 08, AbCellera Biologics Inc.’s ABCL share price has dipped by 8.19%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,737.6 | $1,774.7 | 52% |
|
| Shares Out (Mil) | 303.1 | 94.8 | 83% |
|
| Institutional Ownership | 58.2% | 90.1% | 38% |
|
| Float (Mil) | 205.1 | 69.9 | 75% |
|
| Beta | 1.20 | 1.20 | 70% |
|
| Avg Daily Volume (000s) | 4,813 | 838 | 92% |
|
| Price Change (52-week) |
21.3% | 81.0% | 63% |
|
| Growth | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (20.3%) | 7.8% | 2% |
|
| Net Income (5yr) | (26.4%) | (13.7%) | 16% |
|
| EPS (5yr) | (25.3%) | 0.7% | 10 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.1%) | (15.0%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 6 | 4 | |
| Current EPS | ($0.165) | ($0.650) | ($0.720) | |
| Month Ago EPS | ($0.165) | ($0.650) | ($0.720) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.190) | ($0.710) | ($0.783) | |
| Year/Year Chg | 16.2% | 32.7% | 61.2% | |
| Financials | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $79 | $763 | 24% |
|
| Net Income (TTM) (Mil) | ($144) | ($14) | 8% |
|
| EPS (TTM) | ($0.480) | ($0.200) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | ($153) | $53 | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($83) | ($5) | 15% |
|
| Long-Term Debt (Q1) (Mil) | $134 | $270 | 47% |
|
| Enterprise Value (Q1) (Mil) | $1,236 | $2,430 | 43% |
|
| Valuation | ABCL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.84 | 3.00 | 48% |
|
| P/E | na | 43.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.3 | na |
|
| Ratios | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (141.1%) | 47.6% | 1% |
|
| Net Margin | (181.7%) | (2.9%) | 5% |
|
| ROA | (10.9%) | (3.2%) | 25% |
|
| ROE | (14.7%) | (4.5%) | 26% |
|
| Liabilities to Assets | 28.2% | 43.0% | 20% |
|
| F-Score | 4 | 5 | 34% |
|
AbCellera Biologics Inc. did not pass any screens on 7/30/2026.
